Stock Market Live May 5, 2026: S&P 500 (SPY) Bounces on Pullback in Oil

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Aug 23, 2017 at 10:30 AM EDT

Ultragenyx Stumbles Over Late-Stage Trial

Ultragenyx Pharmaceutical shares took a turn for the worse on Wednesday after a report that results from its late-stage trial…

Chris Lange | Aug 23, 2017 at 9:50 AM EDT

Intra-Cellular Soars on Critical FDA Update

Intra-Cellular Therapies saw its shares make an incredible gain early on Wednesday after the FDA gave a positive regulatory update…

Chris Lange | Aug 22, 2017 at 9:15 AM EDT

Krystal Biotech Files for IPO

Gene therapy company Krystal Biotech has filed with the SEC regarding its initial public offering.

Jon C. Ogg | Aug 21, 2017 at 12:40 PM EDT

Analysts Say Sienna Biopharmaceuticals Stock Could Run 50% to 100%

The quiet period for Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA) is over after its initial public offering. The Westlake Village, California-based…

Chris Lange | Aug 21, 2017 at 12:39 PM EDT

Coherus Bio Jumps on Private Placement

Coherus Biosciences, Inc. (NASDAQ: CHRS) watched its shares jump on Monday after the company announced that it plans to raise…

Chris Lange | Aug 21, 2017 at 11:38 AM EDT

Ironwood Pharma Muted Despite FDA Approval

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) shares remained relatively muted on Monday after the firm announced a key U.S. Food and…

Chris Lange | Aug 21, 2017 at 9:20 AM EDT

Syros Pharma Wins Orphan Designation From FDA

Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) saw its shares make a handy gain early on Monday after the firm announced a…

Chris Lange | Aug 17, 2017 at 12:15 PM EDT

Valeant Pharmaceuticals Gets Boost From FDA Update

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) saw its shares make a handy gain on Thursday after the company provided an…

Chris Lange | Aug 16, 2017 at 12:15 PM EDT

FibroGen Prices Follow-On Offering

Shares of FibroGen saw a handy gain on Wednesday after the biopharmaceutical company announced the pricing of its underwritten follow-on…

Paul Ausick | Aug 15, 2017 at 4:19 PM EDT

Government Share of ACA Premium Hikes Adds $194 Billion to Federal Deficit

The Congressional Budget Office has estimated that maintaining cost-sharing reduction payments to health insurers will add $194 billion to the…

Jon C. Ogg | Aug 14, 2017 at 3:52 PM EDT

How Kala Pharmaceuticals Could Rise 100% to 200%

Kala Pharmaceuticals, Inc. (NASDAQ: KALA) is a recent initial public offering that could come blessed with magical upside if its…

Chris Lange | Aug 14, 2017 at 10:10 AM EDT

Zynerba Midstage Cannabinoid Trial Falls Short

Zynerba Pharmaceuticals saw its shares sink to a 52-week low after the firm announced results from its midstage trial evaluating…

John Harrington | Aug 11, 2017 at 3:38 PM EDT

Alcoholism Rises in US; Study Says 1 in 8 Adults Considered to Be an Alcoholic

The rate alcohol use disorder, also known as alcoholism, rose by 49% in the first decade of the 2000s, according…

Chris Lange | Aug 10, 2017 at 8:50 AM EDT

Major Biotechs Send Short Sellers Running for Cover

The July 31 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Aug 10, 2017 at 8:40 AM EDT

Short Sellers Hike Bets in Major Pharma

The July 31 short interest data have been compared with the previous figures, and short interest in most of these…

1 … 158 159 160 161 162 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Ultragenyx Stumbles Over Late-Stage Trial

Intra-Cellular Soars on Critical FDA Update

Krystal Biotech Files for IPO

Analysts Say Sienna Biopharmaceuticals Stock Could Run 50% to 100%

Coherus Bio Jumps on Private Placement

Ironwood Pharma Muted Despite FDA Approval

Syros Pharma Wins Orphan Designation From FDA

Valeant Pharmaceuticals Gets Boost From FDA Update

FibroGen Prices Follow-On Offering

Government Share of ACA Premium Hikes Adds $194 Billion to Federal Deficit

How Kala Pharmaceuticals Could Rise 100% to 200%

Zynerba Midstage Cannabinoid Trial Falls Short

Alcoholism Rises in US; Study Says 1 in 8 Adults Considered to Be an Alcoholic

Major Biotechs Send Short Sellers Running for Cover

Short Sellers Hike Bets in Major Pharma

Stock Market Live May 5, 2026: S&P 500 (SPY) Bounces on Pullback in Oil

Live Nasdaq Composite: Tech Stock Gains Unleashed as Stars Align for Risk-On Trade

Pete Buttigieg’s 2024 antitrust win just erased 17,000 jobs and the largest U.S. ultra-low-cost ariline

Oil’s Decline Opens the Door on These 4 Sub-$30 Buys

BofA Just Deemed Ulta Beauty a High-Quality Compounder. Time to Buy the 26% Pullback?

The IRA and 401(K) Tax Trap That Catches Retirees off Guard

Is College Still Worth It? Ron Lieber's Advice for Parents Navigating Shifting Job Market

Pete Buttigieg’s 2024 antitrust win just erased 17,000 jobs and the largest U.S. ultra-low-cost ariline

Oil’s Decline Opens the Door on These 4 Sub-$30 Buys

Health and Healthcare Articles

All Health and Healthcare Articles

Ultragenyx Stumbles Over Late-Stage Trial

Intra-Cellular Soars on Critical FDA Update

Krystal Biotech Files for IPO

Analysts Say Sienna Biopharmaceuticals Stock Could Run 50% to 100%

Coherus Bio Jumps on Private Placement

Ironwood Pharma Muted Despite FDA Approval

Syros Pharma Wins Orphan Designation From FDA

Valeant Pharmaceuticals Gets Boost From FDA Update

FibroGen Prices Follow-On Offering

Government Share of ACA Premium Hikes Adds $194 Billion to Federal Deficit

How Kala Pharmaceuticals Could Rise 100% to 200%

Zynerba Midstage Cannabinoid Trial Falls Short

Alcoholism Rises in US; Study Says 1 in 8 Adults Considered to Be an Alcoholic

Major Biotechs Send Short Sellers Running for Cover

Short Sellers Hike Bets in Major Pharma

Stock Market Live May 5, 2026: S&P 500 (SPY) Bounces on Pullback in Oil

Live Nasdaq Composite: Tech Stock Gains Unleashed as Stars Align for Risk-On Trade

Pete Buttigieg’s 2024 antitrust win just erased 17,000 jobs and the largest U.S. ultra-low-cost ariline

Oil’s Decline Opens the Door on These 4 Sub-$30 Buys

BofA Just Deemed Ulta Beauty a High-Quality Compounder. Time to Buy the 26% Pullback?

Featured Reads

The IRA and 401(K) Tax Trap That Catches Retirees off Guard

Is College Still Worth It? Ron Lieber's Advice for Parents Navigating Shifting Job Market